The expert advisory group for this health technology assessment (HTA) was established to assess the clinical and economic impact of transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis at low and intermediate surgical risk. The public and/or patient (PPI) representatives were involved in supporting HIQA to fulfil its health technology assessment function. All expert advisory group members provided input into the process (for example, forming the terms of reference, drafting key considerations in the report, interpreting research findings) and they also provide peer review of the project report. The public and/or patient representatives were engaged from June to December 2019. The expert advisory group met twice during this period.
The HIQA expert advisory group for HTA of transcatheter aortic valve implantation (TAVI) comprises of 10 members, including one patient and/or public representatives. The PPI representative was identified by a relevant stakeholder organisation, who nominated a representative to participate in an expert advisory group for the duration of the project. There was no specific eligibility criteria. The expert advisory group members were provided with draft written terms of reference for their role, and they were involved in finalisation process.